Endeavor BioMedicines
Small-molecule and biologic therapeutics for life-threatening diseases
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2018
- Latest Form D
- $133M, May 2024
- Total capital
- $222M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $222M
- 2 Form D · last May 2024
- 30 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 15 pending · first 2023
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$133M
- Private capital raisedForm D · SEC · 1st filing$89.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Miguel de los RiosResearcherExecutive OfficerLinked by 6 patents
- Bernard DavitianDirectorNamed in SEC Form D filings
- Chris KruegerExecutive OfficerNamed in SEC Form D filings
- Enoch KariukiExecutive OfficerNamed in SEC Form D filings
- John HoodExecutive Officer, DirectorNamed in SEC Form D filings
- Karan Cheong TakharDirectorNamed in SEC Form D filings
Show all 11 people
- Monal Cheong MehtaDirectorNamed in SEC Form D filings
- Patrick G. EnrightDirectorNamed in SEC Form D filings
- Raghu SaripalliExecutive OfficerNamed in SEC Form D filings
- Vishaal TurakhiaExecutive OfficerNamed in SEC Form D filings
- Wing Cheong LamDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 22- GrantedMethods Of Improving Lung FunctionUSPTOUS 12,605,379
- GrantedMethods Of Treating FibrosisUSPTOUS 12,605,377
- GrantedMethods Of Improving Lung FunctionUSPTOUS 12,605,380
Show all 22 patent records
- Methods Of Improving Lung FunctionApr 21, 2026 · US 12,605,379Granted
- Methods Of Treating FibrosisApr 21, 2026 · US 12,605,377Granted
- Methods Of Improving Lung FunctionApr 21, 2026 · US 12,605,380Granted
- Methods Of Improving Lung FunctionOct 21, 2025 · US 12,447,148Granted
- Methods Of Treating FibrosisJul 24, 2025 · Application 19177041Pending
- Methods Of Treating FibrosisMay 13, 2025 · US 12,295,954Granted
- Methods Of Treating FibrosisFeb 4, 2025 · US 12,213,974Granted
- Method Of Treating Cancer Having An Activated Hedgehog PathwayJun 15, 2023 · Application 18078655Pending
- Method Of Treating FibrosisApr 18, 2023 · US 11,628,167Granted
- Method Of Treating Cancer Having An Activated Hedgehog PathwayApplication 63315803Pending
- Method Of Treating Cancer Having An Activated Hedgehog PathwayApplication 63287832Pending
- Method Of Treating FibrosisApplication PCTUS2021054713Pending
- Methods Of Treating FibrosisApplication 19679193Pending
- Methods Of Treating FibrosisApplication 63091128Pending
- Methods Of Treating FibrosisApplication PCTUS2025018800Pending
- Methods Of Improving Lung FunctionApplication PCTUS2025018407Pending
- Methods Of Improving Lung FunctionApplication 63711648Pending
- Methods Of Improving Lung FunctionApplication 63649067Pending
- Methods of Treating FibrosisApplication 63562488Pending
- Methods And Compositions For Treating Pulmonary FibrosisApplication 63561444Pending
- Methods Of Treating FibrosisApplication PCTUS2024017611Pending
- Method Of Treating Cancer Having An Activated Hedgehog PathwayApplication PCTUS2022081299Pending
Related companies, and why
- Seaport TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Rivus PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Cyclerion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- AbsciSimilar federal contract value in Biotech · null in contracts
- Generation BioSimilar federal contract value in Biotech · null in contracts
- Renibus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .